CTOs on the Move

Cahaba Family Medicine

www.cahabafamilymedicine.com

 
Cahaba Family Medicine Residency is an unopposed, community-based family medicine training program dually accredited by both the ACGME and AOA. Resurrection Family Medicine is now the Cahaba Urban Residency.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Abraxis Oncology

Abraxis Oncology is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sanford House

Sanford House in Grand Rapids, Michigan is a drug and alcohol rehab and recovery center. We offer residential and non-residential treatment options for both men and women in Michigan and across the country. Our Johns Street location provides detox for ...

Nexelis, a Q² Solutions

On the Forefront of COVID-19 Recognized leader in the COVID-19 field by governmental and non-governmental organizations as the reference assay...

Longboard Pharmaceuticals

Longboard Pharmaceuticals, Inc. (Longboard) is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Longboard was formed in January 2020 by Arena Pharmaceuticals, Inc. (Arena) to advance a portfolio of centrally acting product candidates designed to be highly selective for specific G protein-coupled receptors (GPCRs). Longboard`s small molecule product candidates were discovered out of the same platform at Arena that represents a culmination of more than 20 years of GPCR research. Longboard is evaluating LP352, an oral, centrally acting, 5-hydroxytryptamine 2c receptor subtype superagonist, in development for the potential treatment of developmental and epileptic encephalopathies. Longboard is also evaluating LP143, a centrally acting, full cannabinoid type 2 receptor agonist, in development for the potential treatment of neurodegenerative diseases associated with neuroinflammation caused by microglial activation, and LP659, a centrally acting, sphingosine-1-phosphate receptor subtypes 1 and 5 modulator, in development for the potential treatment of central nervous system neuroinflammatory diseases.